UB Paderborn / Katalog / Suche / in CDI

Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial

The Lancet (British edition), 2016-12, Vol.388 (10063), p.2997-3005

2016

Link zum Volltext

Verfügbarkeit prüfen

Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase

Endocrine-related cancer, 2010-06, Vol.17 (2), p.351-360

2010

Link zum Volltext

Verfügbarkeit prüfen

PARP3 inhibitors ME0328 and olaparib potentiate vinorelbine sensitization in breast cancer cell lines

Breast cancer research and treatment, 2018-11, Vol.172 (1), p.23-32

2018

Link zum Volltext

Verfügbarkeit prüfen

Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer

PloS one, 2016-12, Vol.11 (12), p.e0167906

2016

Link zum Volltext

Verfügbarkeit prüfen

Precision spherical nucleic acids for delivery of anticancer drugs

Chemical science (Cambridge), 2017-09, Vol.8 (9), p.6218-6229

2017

Link zum Volltext

Verfügbarkeit prüfen

The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines

Investigational new drugs, 2013-04, Vol.31 (2), p.461-468

2013

Link zum Volltext

Verfügbarkeit prüfen

PARP Inhibition Sensitizes Breast Cancer Cells to Eribulin

Frontiers in bioscience (Landmark. Print), 2023-03, Vol.28 (3), p.52-52

2023

Link zum Volltext

Verfügbarkeit prüfen

Different impact of excision repair cross-complementing group 1 on survival

Journal of clinical oncology, 2010-04, Vol.28 (10), p.e163; author reply e164-e163

Panasci, Lawrence C

2010

Link zum Volltext

Verfügbarkeit prüfen

Pegylated Liposomal Doxorubicin and Trastuzumab in HER-2 Overexpressing Metastatic Breast Cancer: A Multicenter Phase II Trial

Journal of clinical oncology, 2006-06, Vol.24 (18), p.2773-2778

2006

Link zum Volltext

Verfügbarkeit prüfen

Are frailty markers useful for predicting treatment toxicity and mortality in older newly diagnosed cancer patients? Results from a prospective pilot study

Critical reviews in oncology/hematology, 2011-05, Vol.78 (2), p.138-149

2011

Link zum Volltext

Verfügbarkeit prüfen

The risks associated with the widespread use of telemedicine in oncology: Four cases and review of the literature

Cancer reports, 2022-07, Vol.5 (7), p.e1531-n/a

2022

Link zum Volltext

Verfügbarkeit prüfen

Xenografts of Human Hepatocellular Carcinoma: A Useful Model for Testing Drugs

Clinical cancer research, 2006-07, Vol.12 (14), p.4306-4314

2006

Link zum Volltext

Verfügbarkeit prüfen

Clinical Practice Patterns in Chemotherapeutic Treatment Regimens for Metastatic Colorectal Cancer

Clinical colorectal cancer, 2016-06, Vol.15 (2), p.135-140

2016

Link zum Volltext

Verfügbarkeit prüfen

Phase II Multicenter Trial of Anthracycline Rechallenge With Pegylated Liposomal Doxorubicin Plus Cyclophosphamide for First-Line Therapy of Metastatic Breast Cancer Previously Treated With Adjuvant Anthracyclines

Journal of clinical oncology, 2009-12, Vol.27 (35), p.5906-5910

2009

Link zum Volltext

Verfügbarkeit prüfen

Chlorambucil cytotoxicity in malignant B lymphocytes is synergistically increased by 2-(morpholin-4-yl)-benzo[h]chomen-4-one (NU7026)-mediated inhibition of DNA double-strand break repair via inhibition of DNA-dependent protein kinase

The Journal of pharmacology and experimental therapeutics, 2007-06, Vol.321 (3), p.848

2007

Link zum Volltext

Verfügbarkeit prüfen

Xrcc3 induces cisplatin resistance by stimulation of Rad51-related recombinational repair, S-phase checkpoint activation, and reduced apoptosis

The Journal of pharmacology and experimental therapeutics, 2005-08, Vol.314 (2), p.495

2005

Link zum Volltext

Verfügbarkeit prüfen

Abstract 300: A new combination therapy to treat metastatic breast cancer

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.300-300

2019

Link zum Volltext

Verfügbarkeit prüfen

Docetaxel plus cyclophosphamide in adjuvant breast cancer

Journal of clinical oncology, 2007-09, Vol.25 (27), p.4327; author reply 4327-4327

2007

Link zum Volltext

Verfügbarkeit prüfen

Effect of tamoxifen after chemotherapy in hormone receptor-positive, node-negative breast cancer

Journal of clinical oncology, 2006-05, Vol.24 (15), p.2392; author reply 2392-2392

Panasci, Lawrence C

2006

Link zum Volltext

Verfügbarkeit prüfen

Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer : Cancer and leukemia Group B study 8662

Clinical cancer research, 2001-09, Vol.7 (9), p.2703-2711

2001

Link zum Volltext

Verfügbarkeit prüfen

An antisense oligonucleotide targeted to human Ku86 messenger RNA sensitizes M059K malignant glioma cells to ionizing radiation, bleomycin, and etoposide but not DNA cross-linking agents

Cancer research (Chicago, Ill.), 2002-10, Vol.62 (20), p.5888-5896

2002

Link zum Volltext

Verfügbarkeit prüfen

Small Molecules, Inhibitors of DNA-PK, Targeting DNA Repair, and Beyond

Frontiers in pharmacology, 2013-01, Vol.4, p.5

2013

Link zum Volltext

Verfügbarkeit prüfen

Can high Ki67 predict distant recurrence in early-stage breast cancer with low Oncotype Dx score?

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e12561-e12561

2021

Link zum Volltext

Verfügbarkeit prüfen

The phosphatidylinositol‐3 kinase I inhibitor BKM120 induces cell death in B‐chronic lymphocytic leukemia cells in vitro

International journal of cancer, 2013-07, Vol.133 (1), p.247-252

2013

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial

Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase

PARP3 inhibitors ME0328 and olaparib potentiate vinorelbine sensitization in breast cancer cell lines

Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer

Precision spherical nucleic acids for delivery of anticancer drugs

The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines

PARP Inhibition Sensitizes Breast Cancer Cells to Eribulin

Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases

Different impact of excision repair cross-complementing group 1 on survival

Pegylated Liposomal Doxorubicin and Trastuzumab in HER-2 Overexpressing Metastatic Breast Cancer: A Multicenter Phase II Trial

Are frailty markers useful for predicting treatment toxicity and mortality in older newly diagnosed cancer patients? Results from a prospective pilot study

The risks associated with the widespread use of telemedicine in oncology: Four cases and review of the literature

Xenografts of Human Hepatocellular Carcinoma: A Useful Model for Testing Drugs

Clinical Practice Patterns in Chemotherapeutic Treatment Regimens for Metastatic Colorectal Cancer

Phase II Multicenter Trial of Anthracycline Rechallenge With Pegylated Liposomal Doxorubicin Plus Cyclophosphamide for First-Line Therapy of Metastatic Breast Cancer Previously Treated With Adjuvant Anthracyclines

Chlorambucil cytotoxicity in malignant B lymphocytes is synergistically increased by 2-(morpholin-4-yl)-benzo[h]chomen-4-one (NU7026)-mediated inhibition of DNA double-strand break repair via inhibition of DNA-dependent protein kinase

Xrcc3 induces cisplatin resistance by stimulation of Rad51-related recombinational repair, S-phase checkpoint activation, and reduced apoptosis

Abstract 300: A new combination therapy to treat metastatic breast cancer

Docetaxel plus cyclophosphamide in adjuvant breast cancer

Effect of tamoxifen after chemotherapy in hormone receptor-positive, node-negative breast cancer

Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer : Cancer and leukemia Group B study 8662

An antisense oligonucleotide targeted to human Ku86 messenger RNA sensitizes M059K malignant glioma cells to ionizing radiation, bleomycin, and etoposide but not DNA cross-linking agents

Small Molecules, Inhibitors of DNA-PK, Targeting DNA Repair, and Beyond

Can high Ki67 predict distant recurrence in early-stage breast cancer with low Oncotype Dx score?

The phosphatidylinositol‐3 kinase I inhibitor BKM120 induces cell death in B‐chronic lymphocytic leukemia cells in vitro

Suchergebnisse filtern